Vicore Pharma Holding AB
VCRE
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.3B
$11.59
▲ +0.35%
P/E
-11.74
Mkt Cap
$3.3B
52-Wk Range
$10.47–$17.80
52-Week Range
$10.47 - $17.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 28.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-28.7% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying VCRE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 21, 2026
Reported EPS of -$0.05 vs -$0.04 consensus (-24.4% surprise). Revenue of $226.6K vs $59.1K expected (+283.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-24.4%
Revenue trend · last 4Q
—
—
—
—
Q3 25
Q4 25
Q1 26
Q2 26
$8.5K
$44.0K
$63.2K
$24.0K
Margins · last 4Q
Profit
-6454.8%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How VCRE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.